Tumor necrosis factor ligand superfamily member 13B — Drug Target

All drugs that target Tumor necrosis factor ligand superfamily member 13B — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

B Lymphocyte Stimulator-specific Inhibitor [EPC]

Marketed (2)

• Benlysta · GlaxoSmithKline · Oncology
• Lymphostat B · Human Genome Sciences Inc. · B Lymphocyte Stimulator-specific Inhibitor [EPC] · Oncology
  Belimumab works by blocking the B Lymphocyte Stimulator, a protein that can contribute to the autoimmune response in Systemic lupus erythematosus.